• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：基础与临床药理学综述

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.

作者信息

Kalra Sanjay

机构信息

Bharti Hospital and B.R.I.D.E., Karnal, India,

出版信息

Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.

DOI:10.1007/s13300-014-0089-4
PMID:25424969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4269649/
Abstract

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.

摘要

钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类新开发的口服抗糖尿病药物（OADs），其作用机制独特。本综述描述了SGLT2抑制剂应用的生物化学和生理学基础，以及它们的临床药理学，包括作用机制和剂量学。还讨论了这些药物在现有口服抗糖尿病药物领域中的实际应用情况。

相似文献

1
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：基础与临床药理学综述
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.
2
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病治疗中的作用
Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16.
3
Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：抗糖尿病药物中的新成员。
Cardiovasc Drugs Ther. 2014 Aug;28(4):331-4. doi: 10.1007/s10557-014-6522-0.
4
A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.基于网络药理学的钠-葡萄糖共转运蛋白 2 抑制剂治疗糖尿病和心力衰竭的药理机制的生物信息学研究。
Cardiovasc Drugs Ther. 2022 Aug;36(4):713-726. doi: 10.1007/s10557-021-07186-y. Epub 2021 May 24.
5
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂治疗 2 型糖尿病的药效学、疗效和安全性。
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
6
Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.钠-葡萄糖共转运蛋白 2 抑制剂可降低糖尿病小鼠中的琥珀酸水平。
World J Gastroenterol. 2020 Jun 21;26(23):3225-3235. doi: 10.3748/wjg.v26.i23.3225.
7
Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2-Is）的使用与下肢截肢风险。
Curr Drug Saf. 2021;16(1):62-72. doi: 10.2174/1574886315666200805103053.
8
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.在接受 SGLT2 抑制剂治疗的急性心肌梗死合并糖尿病患者中，梗死面积、炎症负担和入院高血糖。一项多中心国际注册研究。
Cardiovasc Diabetol. 2022 May 15;21(1):77. doi: 10.1186/s12933-022-01506-8.
9
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.对严重皮肤和皮下组织疾病的易感性和钠依赖性葡萄糖共转运蛋白 2 型（SGLT2）抑制剂的皮肤组织分布。
Int J Med Sci. 2018 Jun 13;15(9):937-943. doi: 10.7150/ijms.22224. eCollection 2018.
10
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病患者中的利弊：一项系统评价和荟萃分析
PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125. eCollection 2016.

引用本文的文献

1
Risk factors of urinary tract infections with sodium-glucose cotransporter-2 inhibitors in heart failure.心力衰竭患者使用钠-葡萄糖协同转运蛋白2抑制剂发生尿路感染的危险因素。
Medicine (Baltimore). 2025 Jul 11;104(28):e43245. doi: 10.1097/MD.0000000000043245.
2
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study.达格列净对2型糖尿病合并慢性冠状动脉综合征行经皮冠状动脉介入治疗患者的心肾保护作用：一项注册横断面研究
Cardiovasc Diabetol. 2025 Apr 26;24(1):185. doi: 10.1186/s12933-025-02678-9.
3
Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments.糖尿病及相关血管疾病：发病机制、并发症与不断发展的治疗方法
Adv Ther. 2025 Jun;42(6):2659-2678. doi: 10.1007/s12325-025-03185-9. Epub 2025 Apr 19.
4
Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy.使用新型葡萄糖激酶激活剂对PI3Kα抑制剂诱导的高血糖进行治疗管理：推进PI3Kα抑制剂治疗的前沿进展。
Mol Metab. 2025 Jun;96:102151. doi: 10.1016/j.molmet.2025.102151. Epub 2025 Apr 14.
5
Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes.老年体弱2型糖尿病患者管理面临的挑战、当前创新举措及机遇：欧洲老年医学学会（EuGMS）糖尿病特别兴趣小组立场文件
Eur Geriatr Med. 2025 Feb 27. doi: 10.1007/s41999-025-01168-1.
6
Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.达格列净、格列美脲和缓释二甲双胍片固定剂量复方制剂用于二甲双胍和格列美脲控制不佳的2型糖尿病患者：印度一项III期、开放标签、随机临床研究
Diabetes Obes Metab. 2025 Apr;27(4):2193-2205. doi: 10.1111/dom.16218. Epub 2025 Feb 14.
7
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health.钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病中的应用：支持心血管、肾脏及代谢健康
Kidney Med. 2024 Jun 8;6(8):100851. doi: 10.1016/j.xkme.2024.100851. eCollection 2024 Aug.
8
Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.与SGLT2抑制剂相关的皮肤药物不良反应
J Clin Med. 2024 Dec 31;14(1):188. doi: 10.3390/jcm14010188.
9
Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病及非糖尿病患者的血流动力学影响——一项叙述性综述
Healthcare (Basel). 2024 Dec 6;12(23):2464. doi: 10.3390/healthcare12232464.
10
Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.动脉高血压：新的药理学靶点与未来展望
J Clin Med. 2024 Oct 4;13(19):5927. doi: 10.3390/jcm13195927.

本文引用的文献

1
Medication counselling with sodium glucose transporter 2 inhibitor therapy.钠葡萄糖协同转运蛋白2抑制剂治疗的用药咨询
Indian J Endocrinol Metab. 2014 Sep;18(5):597-9. doi: 10.4103/2230-8210.139206.
2
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.探索 SGLT2 抑制剂达格列净在 1 型糖尿病中的潜力：一项随机、双盲、安慰剂对照的初步研究。
Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.
3
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.2型糖尿病管理中SGLT2抑制剂的进展更新
Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014.
4
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.卡格列净在二甲双胍治疗的 2 型糖尿病患者中提供了超过 104 周的持久血糖改善和体重减轻，优于格列美脲：一项随机、双盲、3 期研究。
Diabetes Care. 2015 Mar;38(3):355-64. doi: 10.2337/dc13-2762. Epub 2014 Sep 9.
5
Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?钠-葡萄糖共转运蛋白 2 抑制剂在 1 型糖尿病中的应用：既能降低血糖又能保护肾脏？
Can J Diabetes. 2014 Oct;38(5):356-63. doi: 10.1016/j.jcjd.2014.05.006. Epub 2014 Sep 3.
6
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂卡格列净的药效学效应：一项2型糖尿病患者的随机研究
PLoS One. 2014 Aug 28;9(8):e105638. doi: 10.1371/journal.pone.0105638. eCollection 2014.
7
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.达格列净用于2型糖尿病的安全性概况：总体安全性和罕见事件临床研究的汇总分析
Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4.
8
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.在二甲双胍治疗2型糖尿病控制不佳的患者中，达格列净与格列吡嗪作为附加疗法的血糖疗效2年耐久性比较
Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.
9
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.肾钠葡萄糖协同转运蛋白2抑制剂作为治疗2型糖尿病的一种新的治疗方法：临床数据及作用机制
J Diabetes Investig. 2014 May 4;5(3):265-75. doi: 10.1111/jdi.12214. Epub 2014 Apr 2.
10
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.达格列净可改善肌肉胰岛素敏感性，但会增强内源性葡萄糖生成。
J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27.